Abstract
Primary Epstein-Barr-Virus (EBV)-associated pulmonary lymphoepithelioma-like carcinoma (LELC) is an aggressive rare cancer. Higher incidences have been observed in Asian sub-populations. Multimodal treatment paradigms have emerged as promising novel strategies in the management of advanced NSCLC. In this report, we describe the case of a 34-year-old female patient of Asian origin with a post-partum initial diagnosis of pulmonary LELC. Multimodal treatment with chemoimmunotherapy and hypofractionated irradiation to the primary tumour and main metastatic sites led to a favourable response demonstrating that radiotherapy may potentially augment anti-tumour immunity. To the best of our knowledge, this is the first case report on this novel therapy strategy of multi-site hypofractionated radiotherapy and chemoimmunotherapy for metastatic pulmonary EBV-associated LELC.
Highlights
The casethe wasfirst again moderate hypofractionated radiotherapy was delivered to the metastases in the right femur cussed 06/2021 at multidisciplinary tumour board (MTB) and, after a renewed biopsy of a new lesion of the L5 confirmed and the primary intrathoracic tumour with the inclusion of
In the present case report, we describe the medical history of a young Asian patient with a post-partum and newly diagnosed EBV-associated metastatic pulmonary carcinoma
To the best of our knowledge, this is the first report on multimodal therapy for metastatic pulmonary EBV-associated lymphoepithelioma-like carcinoma (LELC) for moderately hypofractionated radiotherapy to the primary tumour and main metastatic sites
Summary
Epstein-Barr-Virus(EBV)-associated lymphoepithelioma-like carcinoma (LELC) of the lung is an extremely rare, non-small cell lung cancer subtype accounting for approximately. 0.7% of cases [1], predominantly seen in female Asian never-smokers. There is a paucity of data on its optimal management. Contemporary reports describing treatment with immune checkpoint inhibitors (ICIs) have been published [1,2,3,4]. Promising results in the management of advanced NSCLC with the combination of chemoradioimmunotherapy portend the successful application of a multimodal approach in this setting [5]. Diagnostics 2021, 11, 2072 results in the management of advanced NSCLC with the combination of chemoradioim‐. Munotherapy portend the successful application of a multimodal approach in this setting [5]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
